![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Hits Terra Biological Over Misbranding
FDA Hits Terra Biological Over Misbranding
The FDA served Terra Biological a warning letter for marketing a misbranded, unapproved new drug product on its website.
The agency said the San Diego, California-based firm marketed the product CRONaxal (oxaloacetate) with claims that the product could be used to treat or prevent disease, making it a drug for regulatory purposes.
The website claimed the product could be used with chemotherapy for the “clinical dietary management of the metabolic imbalances associated with glial tumors.”
Upcoming Events
-
21Oct